Details
Description
This poster examines claims and electronic health record based indicators of obesity and tobacco use among sodium-glucose co-transporter-2 inhibitor (SGLT-2i) users in the FDA Sentinel System. It was presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Additional Information
Contributors
Presenter(s)
Casie Horgan, Po-Yin Chang, Meg Her, Rebecca Hawrusik, Alexander Peters, Catherine Corey, David J. Graham, Judith C. Maro and Noelle M. Cocoros